MOR103 Presentation - MorphoSys

More documents

Recommendations

Info

Multinational Trial: Patient Recruitment Equally-Balanced Geographic Patient Distribution ACR/ARHP 2012 – Washington DC – November 10-14, 2012 Total of n=96 patients treated
Study design 0.3 mg/kg MOR103 (n=25) Placebo (n=12) 1.0 mg/kg MOR103 (n=22) Placebo (n=7) DSMB safety review 1.5 mg/kg MOR103 (n=24) Placebo (n=8) DSMB safety review Follow up period (84 d) Follow up period (84 d) 1 8 15 22 29 113 [day] Dose Administration n = randomized patients ACR/ARHP 2012 – Washington DC – November 10-14, 2012 Follow up period (84 d) Cohort number, dose (mg/kg) period and monitoring Follow up period (84-days) DSMB safety review; Screening (to Cohorts 2 & 3)
Page 1 and 2: Abstract-Number: L11 First in Patie
Page 3 and 4: Disclosures • F. Behrens, M. Oste
Page 5: Anti-GM-CSF Monoclonal Antibody (MO
Page 9 and 10: Baseline Disease Characteristics Ch
Page 11 and 12: Patient Disposition Placebo (n=27)
Page 13 and 14: ACR Response at Week 4 Percentage o
Page 15 and 16: EULAR Response at Week 4 Percentage
Page 17 and 18: Change of Synovitis by MRI Analysis
Page 19 and 20: Acknowledgements Investigators �
Page 21 and 22: Geographic Distribution of Patients
Page 23: DAS28 Response to Treatment MOR103

MOR103 Presentation - MorphoSys

Create successful ePaper yourself

Delete template?

Save as template?